HOME >> MEDICINE >> NEWS
Cancer drug proves effective in treating sickle cell disease

Researchers at the University of Illinois at Chicago College of Medicine have demonstrated that a drug long used to treat cancer is also effective in combating sickle cell disease.

The drug, called decitabine, works even in patients who don't respond to hydroxyurea, the standard treatment, and appears to produce fewer side effects.

"The results of our study are compelling," said Joseph DeSimone, professor of hematology and oncology and a member of the UIC Cancer Center. "Clearly, decitabine is an effective therapy for patients who do not benefit from the traditional treatment. It is possibly even an improvement, although more studies will have to be done."

The clinical trial was conducted at the University of Illinois Medical Center at Chicago, which houses the area's only clinic specializing in sickle cell disease. Results of the study will appear in the June 1 issue of the scientific journal Blood.

Sickle cell disease is caused by a single mutation in a gene that manufactures hemoglobin, the molecule in red blood cells that delivers oxygen to tissues throughout the body.

The defective form of hemoglobin, called hemoglobin S (for sickle), causes serious health problems. Red blood cells take on a characteristic crescent, or sickle, shape and stick to blood vessel walls.

As a result, the cells cannot squeeze through capillaries. Blood supply is blocked, depriving tissues and organs of oxygen and causing short- and long-term damage. Patients suffer episodes of intense pain, typically in the arms, legs and back, but also in the liver, kidney and abdomen.

In some severe cases, transfusions may be required because the aberrant red blood cells have a much shorter life span than normal red blood cells (10 days vs. 100) and the body can't manufacture enough new red blood cells to keep up, leading to anemia.

Patients may also suffer what is called acute chest syndrome, a particularly serious complication and th
'"/>

Contact: Sharon Butler
sbutler@uic.edu
312-355-2522
University of Illinois at Chicago
17-May-2002


Page: 1 2 3

Related medicine news :

1. Cancer in patients with hepatitis C
2. Olson family donates $1 million to Arizona Cancer Center
3. Cancer vaccines: A two-pronged attack?
4. Mayo Clinic Cancer Center receives SPORE grant for brain cancer research from NCI
5. ESMO and Imedex announce partnership for the World Congress on Gastrointestinal Cancer
6. UT Southwestern Moncrief Cancer Center is first in Texas to treat patients with TomoTherapy
7. Cancer researchers seek to predict tumor growth
8. UGA professor receives $3 million grant from National Cancer Institute for breast cancer research
9. Cancer patients in Europe unite with doctors
10. Fox Chase Cancer Center researchers identify novel target for detecting ovarian cancer in blood
11. Cancer burden seen even many years after diagnosis

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/21/2017)... ... January 21, 2017 , ... Salveo for life, a ... bringing its product to the United States as part of its presence to expand ... years, Alcovit aims to reduce the productions of nasty toxins as a result of ...
(Date:1/21/2017)... (PRWEB) , ... January 21, 2017 , ... ... Redwood Family Dermatology has recently joined their multi-specialty medical group. The ... range of cosmetic services. , “We’re excited to add this excellent dermatology practice ...
(Date:1/20/2017)... ... January 20, 2017 , ... A new partnership between Goodwill® ... no longer use or need, from clothes to couches to dressers and bicycles. Roadie ... take them to the nearest Goodwill donation center through February 28th. , “January ...
(Date:1/20/2017)... ... ... Lice Troopers, the lice removal company based in South Florida, has seen a ... , “It happens every year around this time,” says owner, Arie Harel. “Many ... the head-to-head gateway that lice need to spread.” , As children return to classrooms ...
(Date:1/20/2017)... ... January 20, 2017 , ... Vitamin ... alternative VW+ 002. The drinks have been produced in collaboration with Zlatan Ibrahimovic ... during your workout. , After a successful launch in Sweden last year, the ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 19, 2017 Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase ... The global anti-obesity drugs market is expected to ... the forecast period and CAGR of 38.7% in the second half ... a CAGR of 32.8% from 2016 to 2027. The market is ... $24,063 million in 2027. ...
(Date:1/19/2017)... -- Accuray Incorporated (Nasdaq: ARAY ) announced ... set the bar for excellence in customer satisfaction. The ... rating among radiation treatment delivery systems in the U.S., ... Briefing™. The most recent ratings trend also shows Accuray ... for 11 of the past 12 quarters. ...
(Date:1/19/2017)... LONDON , January 19, 2017 ... Grothey ; European Oncology & Haematology, 2016;12(Suppl 2):3-8; ... ... http://photos.prnewswire.com/prnh/20151014/276718LOGO) Published recently in ... the peer-reviewed journal from touchONCOLOGY, an article by ...
Breaking Medicine Technology:
Cached News: